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Staphylococcal toxic shock syndrome (TSS) was originally 
described in menstruating women and linked to TSS toxin 
1 (TSST-1)–producing Staphylococcus aureus. Using UK 
national surveillance data, we ascertained clinical, molec-
ular and superantigenic characteristics of TSS cases. Av-
erage annual TSS incidence was 0.07/100,000 population. 
Patients with nonmenstrual TSS were younger than those 
with menstrual cases but had the same mortality rate. Chil-
dren <16 years of age accounted for 39% of TSS cases, 
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most caused by burns and skin and soft tissue infections. 
Nonmenstrual TSS is now more common than menstrual 
TSS in the UK, although both types are strongly associated 
with the tst+ clonal complex (CC) 30 methicillin-sensitive 
S. aureus lineage, which accounted for 49.4% of all TSS 
and produced more TSST-1 and superantigen bioactivity 
than did tst+ CC30 methicillin-resistant S. aureus strains. 
Better understanding of this MSSA lineage and infections 
in children could focus interventions to prevent TSS in 
the future.
Staphylococcal toxic shock syndrome (TSS) is a life-threatening illness characterized by fever, rash, des-
quamation, organ dysfunction, and shock. In 1980, the use 
of highly absorbent tampons in the United States triggered 
an outbreak of menstrual TSS (mTSS) in young women, 
and TSS incidence peaked at 13.7/100,000 population (1). 
Changes in tampon manufacture and advice regarding 
tampon use helped halt the epidemic. TSS is a notifiable 
illness in the United States; in 2004–2014, average an-
nual incidence varied from 0.03–0.05/100,000 population 
(2). In the United Kingdom and other countries in Eu-
rope, staphylococcal TSS is not a notifiable illness, so the 
clinical, microbiological, and toxigenic features of TSS 
remain poorly described.
TSS is attributed to staphylococcal superantigens that 
cause massive T-cell activation and cytokine release (3). 
TSS toxin 1 (TSST-1) is associated with 95% of mTSS cas-
es and 50% of TSS cases caused by nonmenstrual infective 
foci (nmTSS) (4). Although 24 different staphylococcal su-
perantigens have been described, including staphylococcal 
enterotoxin (SE) and enterotoxin-like superantigens (5), SE 
types A, B, and C are implicated in remaining nmTSS cases 
(3,6), despite the lack of data from Europe.
TSST-1 is encoded by the gene tst, which is carried 
on mobile genetic elements (MGE) named staphylococcal 
pathogenicity islands (SaPIs) that lie within the S. aureus 
chromosome. SaPIs are linked to specific S. aureus genet-
ic families, known as lineages (7). Within human S. au-
reus strains, tst is carried on SaPI1, SaPI2, and SaP68111 
(8,9). Known regulators of tst include the S. aureus acces-
sory gene regulator operon (agr) via the effector molecule 
RNAIII (10), the staphylococcal respiratory response regu-
lator AB (SrrAB) (10), a glucose catabolite repressor CcpA 
(11), the staphylococcal accessory regulator A, σB (12) and 
the SaeRS 2-component system (13).
mTSS strains are reported to belong to a single S. au-
reus lineage (14,15) corresponding to multilocus sequence 
type–clonal complex (MLST-CC) 30, a lineage prevalent 
in the United Kingdom (16). Staphylococcal methicillin 
resistance is mediated by mecA or mecC genes within the 
mobile genetic element staphylococcal cassette chromo-
some mec (SCCmec), of which there are 12 types (17,18). 
Methicillin-sensitive S. aureus (MSSA) and methicillin-
resistant S. aureus (MRSA) strains that are members of 
CC30 carry tst on SaPI2 (19,20).
In this study, we aimed to characterize the clinical and 
molecular epidemiology of TSS in England, Wales, and 
Northern Ireland. We further determined superantigen pro-
duction by dominant S. aureus strain types.
Methods
Case Identification
Public Health England (PHE) requests the referral of all 
TSS-associated isolates to the national reference labo-
ratory for characterization, including toxin gene profil-
ing. We identified clinician-diagnosed staphylococcal 
TSS cases from a database of referred S. aureus isolates 
from England, Wales, and Northern Ireland during Janu-
ary 2008–December 2012 using the search term “toxic 
shock syndrome.” Clinical and demographic data from 
the accompanying isolate referral form (online Technical 
Appendix, https://wwwnc.cdc.gov/EID/article/24/2/17-
0606-Techapp1.pdf) that had been recorded contempo-
raneously were scrutinized for accuracy by a clinician 
(H.S.) before inclusion in the study.
We classified TSS cases in patients <16 years of age 
as pediatric. We classified cases in female patients 12–60 
years of age as mTSS if the infection was associated with 
menstruation or positive vaginal culture for S. aureus. We 
classified the remaining cases as nmTSS. All cases had an 
associated S. aureus isolate.
The average annual incidence of TSS was calculated 
as cases per 100,000 population using Office for National 
Statistics UK population estimates (http://www.ons.gov.
uk/ons/datasets-and-tables/index.html) and was based on 
data from 2009 and later (due to changes in reporting prac-
tice from November 2008 prompted by national guidance 
on toxin-producing S. aureus). We used total population 
for the United Kingdom excluding Scotland as the denomi-
nator for all TSS and nmTSS cases; the total female pop-
ulation 12–60 years of age as the denominator for mTSS 
cases, reflecting the age range of this group; and the num-
ber of children <16 years of age as the denominator for 
pediatric cases. We included data from 2008–2012 in all 
other analyses.
Molecular Characterization of Isolates
We made MLST-CC assignments on the basis of se-
quencing the staphylococcal protein A (spa) gene repeat 
region (21) and referencing spa server (http://spa.ridom.
de/mlst.shtml) and MLST (http://saureus.mlst.net) da-
tabases. We performed SCCmec detection, typing, and 
toxin gene profiling (sea-e, seg-j, tst, and pvl only) by 
multiplex PCR (22,23).
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Antimicrobial Susceptibility Testing
For isolates from 2008–2011 (n = 148; online Technical 
Appendix Table 1), we determined antimicrobial MICs 
by agar dilution (24) and interpreted them in accordance 
with European Committee on Antimicrobial Susceptibil-
ity Testing guidelines (http://www.eucast.org). We did 
not determine antimicrobial susceptibilities for isolates 
from 2012.
TSST-1 Production
Based on molecular epidemiologic findings, we assessed 
TSST-1 production in all tst-positive CC30 MSSA isolates 
from the TSS cohort (n = 81), including TSS isolates as-
sociated with bacteremia, skin and soft tissue infections 
(SSTI), and deep infections. We also assessed TSST-1 
production in randomly selected tst-positive CC30 MRSA 
isolates from non-TSS patients (n = 39, including carriage, 
bacteremia, and SSTI isolates) that had been submitted to 
the reference laboratory during the study period (online 
Technical Appendix Table 1). We quantified TSST-1 in 
cell-free broth-culture supernatants by Western blot by 
comparison with purified TSST-1 protein standards (online 
Technical Appendix).
T-Cell Proliferation
We obtained normal-donor peripheral blood mononuclear 
cells (PBMC) from an approved subcollection of the Im-
perial College NHS Trust Tissue Bank (ICHTB reference 
R12023) from anonymized consenting healthy donors. We 
incubated PBMC (1 × 106 cells/mL) with cell-free RPMI 
bacterial supernatants (1:1,000 dilution) prepared from tst-
positive CC30 MSSA isolates from the TSS cohort (n = 77; 
4 of the isolates did not grow in RPMI) and the randomly 
selected tst-positive CC30 MRSA isolates (n = 39) that 
were investigated for TSST-1 production. We cultured the 
PBMC in RPMI medium (Invitrogen, Hemel Hempstead, 
UK) supplemented with 10% fetal calf serum at 37°C for 
48 h in triplicate (25). We measured proliferation after in-
corporating 1.0 μCi/well of [3H] thymidine and allowing an 
additional 16 h incubation.
DNA Sequencing and Analysis
We extracted whole genomic DNA from randomly se-
lected tst-positive CC30 MSSA isolates from the TSS 
cohort (n = 4) and tst-positive CC30 MRSA isolates (n 
= 5) (online Technical Appendix Table 1) (26). We pre-
pared libraries using the Nextera-XT DNA Sample Prep 
Kit (Illumina, Cambridge, UK) and subjected them to 
MiSeq sequencing (Illumina), generating 150 bp reads. 
We deposited data in the GenBank short read archive (ac-
cession no. SRP082305). We mapped reads to MLST-
CC matched reference genomes MRSA252 (GenBank 
accession no. NC_002952.2 (27) or MN8 (accession no. 
NZ_CM000952) using SMALT (http://www.sanger.ac.uk/
resources/software/smalt/) and determined single-nucle-
otide polymorphisms (SNPs) by SAMtools and bcftools 
(28). We performed de novo assemblies using Velvet 
(https://www.ebi.ac.uk/~zerbino/velvet/) and annotated 
them using Prokka (http://www.vicbioinformatics.com/
software.prokka.shtml). We used Artemis (http://www.
sanger.ac.uk/science/tools/artemis) to visualize the map-
ping of sequence reads to the reference strain and manually 
confirm all polymorphisms. For targeted ccpA sequencing, 
we amplified and sequenced DNA using forward primer 1: 
5′- CACAGTGTCGCGTGTTGTTA-3′ and reverse primer 
1: 5′- TAAGCGCATCCCTACTGCAC-3′.
Statistical Analysis
We analyzed data with GraphPad Prism 6.0 (GraphPad Soft-
ware, La Jolla, California, USA). We tested categorical vari-
ables using Fisher exact test or χ2 test. We summarized non-
parametric data by medians and interquartile ranges (IQR) 
and compared 2 groups by Mann-Whitney U test. We sum-
marized parametric data by means and SDs and analyzed 2 
groups by t-test (2-tailed); we considered p<0.05 significant.
Results
Incidence of TSS
During January 2008–December 2012, a total of 195 TSS 
case isolates were referred to PHE. We excluded 15 cases 
from the study (duplicate isolates from the same case, 4 
cases; isolates submitted for quality control testing, 2 cases; 
isolates from cases incorrectly recorded as TSS, 9 cases), 
leaving 180 microbiologically confirmed TSS cases with 
isolates. Because of missing clinical data, we were unable 
to classify 3 isolates as mTSS or nmTSS and could not as-
certain the sex of 1 patient with nmTSS. 
 We considered the apparent rise in cases during 2008–
2009 an artifact of increased clinical awareness of severe 
toxigenic S. aureus disease from late 2008, prompted by 
national guidance on toxin-producing S. aureus (Figure 
1). Beginning in 2009, mTSS referrals declined annually, 
whereas nmTSS cases remained stable. By 2012, cases 
of nmTSS outnumbered mTSS. Overall, most cases were 
nonmenstrual (107, 59.4%). Average annual incidence per 
100,000 population was 0.07 (95% CI 0.05–0.10) for all 
cases, 0.09 (95% CI 0.06–0.14) for menstrual cases, and 
0.04 (95% CI 0.02–0.06) for nonmenstrual cases.
Clinical Characteristics of TSS Patients
Despite an overall preponderance of female case-patients, 
we found no gender difference among nmTSS cases (Table 
1). The median age of the cohort was 19 years; patients 
with nmTSS were younger than those with mTSS (median 
15.0 vs. 21.5 years; p = 0.01).
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 2, February 2018 261
Of the TSS cases studied, 39% (71/180) occurred in 
children <16 years of age; one sixth of all TSS case-patients 
were <1 year of age (Figure 2). The median age of pediatric 
TSS case-patients was 4 years, with an average annual inci-
dence of 0.14/100,000 children (95% CI 0.08–022). How-
ever, among children <1 year of age, the average annual 
incidence increased to 0.45/100,000 (95% CI 0.26–0.79). 
Most pediatric nmTSS cases were related to burns (26.8%, 
15/56) or SSTIs (25%, 14/56). 
Five percent of all patients with TSS had died at the 
time of referral of the isolate. We found no difference in 
fatality rate between mTSS and nmTSS cases and no as-
sociation with age (online Technical Appendix Table 2). 
The infective focus in nmTSS cases was SSTI (n = 41), 
primary bacteremia (n = 15), burns (n = 15), deep abscess 
(n = 13), respiratory tract (n = 10), bone and joint (n = 4), 
unknown (n = 6), and other sites (n = 3). We found no as-
sociation between site of infection and S. aureus lineage 
(online Technical Appendix Figure 1).
Molecular Characteristics of TSS Isolates
Among 180 TSS S. aureus isolates, we identified 88 spa 
types associated with 15 different MLST-CCs (online 
Technical Appendix Table 3). The leading cause of both 
mTSS and nmTSS was CC30 MSSA, accounting for >50% 
of infections (Figure 3), although we found a stronger as-
sociation of CC30 with mTSS than with nmTSS (72.9% 
vs. 36.4%; p<0.0001; online Technical Appendix Table 
3). CC30 MSSA was also the leading cause of TSS among 
pediatric cases (31/71). We identified only 7 MRSA TSS 
isolates (online Technical Appendix Table 4).
TSS isolates carried 3 superantigen genes on average 
(online Technical Appendix Table 5). The most common 
superantigen gene among both mTSS and nmTSS isolates 
was tst (Table 2; online Technical Appendix Figure 2), with 
the exception of the other 2 prevalent superantigen genes, 
seg and sei, that are carried on an enterotoxin gene clus-
ter (egc) along with selm/n/o/u in most S. aureus isolates 
(5). The tst gene was associated with mTSS (Table 2) and 
strongly associated with the CC30 lineage of S. aureus (on-
line Technical Appendix Table 6). The superantigen gene 
sea combined with tst was also linked to mTSS (Table 2), 
whereas sea alone was associated with CC30 (online Tech-
nical Appendix Tables 5, 6); sec was linked to nmTSS (Ta-
ble 2) and CC45 (online Technical Appendix Table 5). Ten 
nmTSS cases were associated with isolates that lacked any 
superantigen gene tested; 7 were CC15, highlighting severe 
disease attributable to this lineage that was unexplained by 
the presence of major superantigens (online Technical Ap-
pendix Tables 5, 6).
Antimicrobial Susceptibility of TSS Isolates
Most isolates were MSSA (mecA negative). The rate of 
resistance to erythromycin was 9.2%; to ciprofloxacin, 
8.5%; to tetracycline, 3.5%; and to teicoplanin, 1.4%. For 
7 mecA-positive MRSA-TSS isolates, the resistance rate to 
ciprofloxacin was 57.1%; to erythromycin, 42.6%; and to 
clindamycin, 14.3%.
As MRSA-related TSS is rarely reported we exam-
ined these cases in more detail. All 7 MRSA cases were 
nonmenstrual, affecting mainly male patients; 3 were as-
sociated with SSTIs. The median patient age was 34 (IQR 
2.3–64.3) years. Five isolates were identified as CC22-SC-
CmecIV, and 4 carried sec, corresponding to the healthcare-
associated MRSA clade dominant in the UK, EMRSA-15; 
MRSA-TSS cases showed a clear association with this 
Figure 1. Staphylococcal TSS cases, England, Wales, and 
Northern Ireland, 2008–2012. The chart depicts the number of 
cases per year of total, menstrual, and nonmenstrual TSS cases 
reported to Public Health England. National guidance on toxin-
producing Staphylococcus aureus disease affected reporting 
practice from November 2008. mTSS, menstrual TSS; nmTSS, 
nonmenstrual TSS; TSS, toxic shock syndrome. 
 
Table 1. Clinical characteristics of staphylococcal toxic shock syndrome cases, United Kingdom, 2008–2012* 
Characteristics All patients, n = 180† Menstrual, n = 70 Nonmenstrual, n = 107 p value 
Median age, y (IQR) 19.0 (9.0–38.3) 21.5 (17 - 35.3) 15.0 (1–43.5) 0.01‡ 
Sex, no. (%) 
    
 F 128 (71.1) 70 (100) 55 (51.4) 0.0001§ 
 M 51 (28.3) 0 51 (47.7)  
 Unknown 0 0 1 (0.9)  
Deaths, no. (%) 9 (5.0) 4 (5.7) 5 (4.7) 0.74§ 
*Boldface indicates a statistically significant result, p<0.05. IQR, interquartile range.  
†3 patient isolates not assigned as menstrual or nonmenstrual due to lack of clinical data 
‡Mann-Whitney U test comparing menstrual and nonmenstrual TSS cases. 
§Fisher exact test comparing menstrual and nonmenstrual TSS cases. 
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lineage (online Technical Appendix Table 4). The remain-
ing CC22 isolate carried tst and belonged to a MRSA 
lineage frequently identified in the Middle East. Only 1 
MRSA-TSS isolate was CC30-SCCmecII, corresponding 
to the UK HA-MRSA clade EMRSA-16. One isolate was 
CC6-SCCmecII and lacked all superantigen genes tested.
TSST-1 Production by CC30 S. aureus
The strong association of CC30 with TSS was unsurpris-
ing because of the presence of tst. We measured TSST-
1 in broth-culture supernatants from tst-positive CC30 
MSSA isolates from the TSS cohort and, for comparison, 
randomly selected clinical tst-positive MRSA isolates that 
belonged to the same lineage (CC30) (20,29) (online Tech-
nical Appendix Table 1).
Of note, 77/81 tst-positive CC30 MSSA isolates pro-
duced detectable TSST-1, compared with 9/39 tst-positive 
CC30 MRSA isolates. The tst-positive CC30 MSSA iso-
lates produced more TSST-1 than did tst-positive CC30 
MRSA isolates, albeit with marked variability (88.5 ± 
48.3 vs. 31.4 ± 18.1 ng/mL,;p<0.0001; Figure 4, panel A). 
Furthermore, the superantigenic activity of isolates, mea-
sured by T-cell proliferation in response to broth-culture 
supernatants, of tst-positive CC30 MSSA strains (164,893 
± 36,191 counts/min) was significantly greater than that 
of tst-positive CC30 MRSA strains  (149,653 ± 30,412 
counts/min; p = 0.02; Figure 4, panel B).
tst-positive CC30 MRSA and Mutation in tst  
Regulator, CcpA
To ascertain the basis for the observed variability in 
TSST-1 production among CC30 S. aureus, we subjected 
4 tst-positive CC30 MSSA isolates from the TSS cohort 
and 5 tst-positive CC30 MRSA clinical isolates to whole-
genome sequencing. The tst gene, promoter, and regulator 
sequences, including SarA, SrrAB, agr, and σB, were iden-
tical among the 9 sequenced strains and reference isolates 
(MN8/MRSA252).
We detected mutations in TSST-1 regulator SaeRS in 
2/4 tst-positive CC30 MSSA isolates; a synonymous SNP 
C481T in SaeR in 1 strain and a nonsynonymous SNP in 
SaeS in another resulted in a change from asparagine to 
serine at aa residue 218. Because these strains produced 
abundant TSST-1 (online Technical Appendix Table 1), we 
did not study these mutations further.
Figure 2. Age distribution of patients with staphylococcal TSS in 
England, Wales, and Northern Ireland, 2008–2012. mTSS, menstrual 
TSS; nmTSS, nonmenstrual TSS; TSS, toxic shock syndrome.
Figure 3. Number of isolates from each Staphylococcus 
aureus clonal complex causing staphylococcal toxic shock 
syndrome in England, Wales, and Northern Ireland, 2008–2012. 
***p<0.0001 by Fisher exact test. mTSS, menstrual TSS; nmTSS, 
nonmenstrual TSS; TSS, toxic shock syndrome; UNK, unknown 
(isolates that failed to grow on subculture).
 
 
 
Table 2. Frequency of major superantigen genes among Staphylococcus aureus isolates associated with menstrual and nonmenstrual 
toxic shock syndrome, United Kingdom, 2008–2012* 
Superantigen gene† 
No. (%) cases 
p value§ Total, n = 180‡ Menstrual, n = 70 Nonmenstrual, n = 107 
sea and tst combined 54 (30.0) 27 (38.6) 25 (23.4) 0.04 
tst alone 37 (20.5) 23 (32.9) 13 (12.1) 0.001 
sea alone 12 (6.7) 4 (5.7) 8 (7.5) 0.77 
seb alone 11 (6.1) 3 (4.3) 8 (7.5) 0.53 
sec alone 14 (7.8) 1 (1.4) 13 (12.1) 0.01 
sed alone 4 (2.2) 0 4 (3.7) 0.15 
*Boldface indicates a statistically significant result. 
†Does not include 48 TSS isolates that did not have sea, seb, sec, sed, or tst in isolation.  
‡Three additional TSS isolates could not be classified as menstrual or nonmenstrual due to lack of clinical data 
§By Fisher exact test comparing the percentage carriage of a given superantigen gene among menstrual and nonmenstrual isolates.  
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We detected a nonsynonymous SNP in the sequence 
of regulator ccpA in all 5 tst-positive CC30 MRSA isolates 
but not in any tst-positive CC30 MSSA isolate. This dif-
ference translated into a change from threonine (ACA) to 
isoleucine (ATA) at aa residue 87/329 (online Technical 
Appendix Figure 3).
To determine the prevalence of the ccpA (T87I) variant 
in CC30, we sequenced ccpA in an additional 34 tst-posi-
tive CC30 MRSA and 19 tst-positive CC30 MSSA isolates 
(online Technical Appendix Table 1). Including genome-
sequenced isolates, 33/39 tst-positive CC30 MRSA isolates 
had ccpA (T87I), compared with 0/23 tst-positive CC30 
MSSA isolates, confirming an association of ccpA (T87I) 
with CC30 MRSA strains. Furthermore, ccpA (T87I) was 
strongly negatively associated with production of TSST-1 
in tst-positive CC30 S. aureus: 26/33 ccpA (T87I) isolates 
did not produce TSST-1, compared with only 1/23 wild-
type ccpA isolates (p<0.0001 by Fisher exact test).
We conducted SCCmec typing on a subset of tst-posi-
tive CC30 MRSA strains (n = 15; online Technical Appen-
dix Table 1). Results demonstrated an association of ccpA 
(T87I) with SCCmecII; 7/11 SCCmecII isolates had ccpA 
(T87I), compared with 0/4 SCCmecIV isolates (p = 0.03 by 
χ2 test). This finding highlights the possibility that reduced 
TSST-1 production might be attributable to either SCCme-
cII or ccpA (T87I).
Discussion
We provide a substantive national clinical and microbio-
logical overview of staphylococcal TSS cases in the United 
Kingdom. TSS incidence was 0.07/100,000 population, 
nmTSS cases now outnumber mTSS cases, and nmTSS 
affects younger persons. The tst-positive CC30 S. aureus 
lineage was linked strongly with TSS and almost all mTSS 
cases. CC30 MSSA is a prevalent lineage in the United 
Kingdom (16), so ongoing surveillance and clinical vigi-
lance for TSS are important. 
Our findings may underestimate TSS incidence be-
cause notification of TSS is voluntary in the United King-
dom and we included only microbiologically confirmed 
cases. These factors increase diagnostic confidence, but 
TSS is a syndromic condition not requiring bacteriological 
confirmation. Overall TSS incidence was low but similar 
to rates in the United States (2); improvements in care may 
account for low overall incidence of TSS, because patients 
may not fulfill all of the criteria required by the case defini-
tion of TSS. The overall TSS incidence in children con-
trasts with findings from a British Pediatric Surveillance 
Unit study in which a higher incidence of combined strep-
tococcal and staphylococcal TSS cases was reported (30).
The number of cases of mTSS fell from 2009 to 2012, 
such that nmTSS cases are now more common than mTSS 
cases, mirroring US trends (31). Patients in our study were 
younger than in US cohorts (31,32), and nmTSS patients 
were younger than those with mTSS. Most nmTSS cases 
occurred in children, with burns and SSTIs as the cause 
in 51.8% (29/56) of these cases. An association between 
nmTSS and increased mortality rate has been reported, al-
though a high incidence of bacteremia may have affected 
the findings of that study (33). It is possible that we did not 
ascertain all cases of TSS, although we found no difference 
in reported deaths between mTSS and nmTSS cases or as-
sociations with age; the overall death rate was 5%.
The association of TSS, and particularly mTSS, with 
a single lineage corresponding to CC30 S. aureus has been 
described in diverse geographic localities (14,15). The tst-
positive CC30 MSSA clone has recently been named epi-
demic MSSA-ST30 because it is responsible for a substantial 
Figure 4. TSST-1 and total mitogen production in vitro by tst-positive clonal complex (CC) 30 MSSA and CC30 MRSA strains. A) Mean 
TSST-1 present in the culture supernatants of tst-positive CC30 MSSA  (n = 81) and CC30 MRSA (n = 39) isolates measured by immunoblot 
after overnight culture in brain–heart infusion broth. B) Mean human PBMC proliferative response to culture supernatants of tst-positive 
CC30 MSSA (n = 77) and CC30 MRSA (n = 39) isolates. Negative indicates RPMI tissue culture medium (Invitrogen, Hemel Hempstead, 
UK) alone. Error bars indicate SDs. *p<0.05; ***p<0.0001 (both by 2-tailed t-test). cpm, counts per minute; MSSA, methicillin-sensitive S. 
aureus; MRSA, methicillin-resistant S. aureus; PBMC, peripheral blood mononuclear cells; TSS, toxic shock syndrome; TSST-1, TSS toxin 1.
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amount of S. aureus disease and is a precursor to the HA-
MRSA clone, EMRSA-16, which has been responsible for 
major national UK MRSA outbreaks (29).
The tst gene was the predominant superantigen gene 
among TSS isolates, excluding seg and sei, which were 
also previously implicated in TSS (34). The superantigens 
seg and sei are carried on the egc, which is widespread in 
S. aureus (5), and are unlikely to have any specific associa-
tion with TSS. We linked tst to mTSS and CC30. Several 
groups have demonstrated similar associations of staphy-
lococcal superantigen genes with specific lineages (35,36), 
due to clonal associations, superantigen arrangements, and 
transmission via mobile genetic elements, although other 
firm associations linking lineage, superantigen gene car-
riage, infection type, and disease presentations have not 
been made. A recent study of atopic dermatitis that exam-
ined the relationship of ethnicity and staphylococcal viru-
lence factors found a lack of tst-positive S. aureus atopic 
dermatitis in African American persons that was consistent 
with an absence of tst-positive S. aureus mTSS among 
this group, suggesting differences in disease presentation 
among disparate ethnic groups (37) based on host charac-
teristics. The ethnicity of the patients with TSS referred to 
PHE in this study was not recorded, and such bacterial ge-
netic associations with disease could not be made but may 
merit consideration in future studies.
Among MSSA isolates, resistance rates to key antimi-
crobial drugs were similar to reported UK MSSA bactere-
mia isolates (38). Notably, teicoplanin resistance was de-
tected, although rarely. This finding circumvents any need 
to change current recommendations for antimicrobial drugs 
for TSS that include a bactericidal cell wall inhibitor (e.g., 
β-lactamase–resistant antistaphylococcal) and protein-syn-
thesis inhibitor (e.g., clindamycin) along with intravenous 
immunoglobulin for severe cases unresponsive to first-line 
therapy and source control (39). No vaccines are available 
to prevent TSS, although a recombinant TSST-1 variant 
vaccine has shown promise in a recent human clinical trial 
and was found to be safe and immunogenic (40).
The MRSA-TSS rate in this study was lower than rates 
in the United States (32), perhaps reflecting the low UK 
community-associated MRSA prevalence (41). All MRSA 
cases were nonmenstrual and mostly associated with recog-
nized healthcare-associated MRSA clones, although we did 
not record the mode of acquisition. Only 1 CC30 MRSA 
(EMRSA-16) isolate caused TSS, even though CC30 is the 
main TSS-associated lineage; this finding mirrors the na-
tional decline in UK EMRSA-16 over time (42).
Isolates of tst-positive CC30 MSSA were more likely 
to produce TSST-1 in vitro and secreted almost 3 times 
more TSST-1 than did tst-positive CC30 MRSA isolates, 
which translated into a functional difference in superanti-
genic activity. We do not know whether such a difference 
would extend to the in vivo setting. Our study of TSST-1 
production was limited by availability of clinical tst+ CC30 
strains; clinical TSS CC30 MSSA strains were therefore 
compared with clinical non-TSS CC30 MRSA strains and 
not to clinical TSS MRSA strains. Thus, more MSSA than 
MRSA strains were from the genital tract or from burns, 
potentially confounding phenotypic differences observed. 
Defining the precise comparator group for TSS CC30 
MSSA isolates is challenging because of lack of TSS 
CC30 MRSA isolates and suitable non-TSS strains referred 
to PHE.
Bacterial acquisition of antimicrobial drug resistance 
elements can be associated with a fitness cost. In the United 
Kingdom, most CC30 HA-MRSA strains carry SCCmecII 
(EMRSA-16; ST36-SCCmecII) that may reduce cytolytic 
toxin production and, in association with fudoh gene car-
riage by this element, reduce hemolytic activity and viru-
lence (43,44). Our findings suggest an association between 
SCCmecII and reduced TSST-1 production that might be 
linked to a SNP in a regulatory gene, ccpA. The resulting 
mutation in CcpA occurs adjacent to a co-repressor binding 
site in the transcriptional regulation region (online Techni-
cal Appendix Figure 3) that could influence tst promoter 
binding and affect TSST-1 secretion. Such SNPs in viru-
lence regulators may have had a role in shaping the health-
care-associated phenotype of EMRSA-16 (20). New tools 
that allow manipulation of previously nontransformable 
lineages such as CC30 will facilitate investigating such ge-
netic mechanisms in S. aureus (45).
Our study shows that the ability to produce TSST-1 
varies widely within the tst-positive CC30 lineage and im-
paired expression is associated with the presence of SC-
CmecII and ccpA (T87I), underlining the potential for ge-
nomic approaches to contribute to greater understanding of 
patterns of clinical disease. Given the prevalence of tst-pos-
itive CC30 MSSA causing TSS and its role as a dominant 
UK lineage of S. aureus, active surveillance of this lineage 
is required. Clarification of the particular modes of trans-
mission, acquisition, and pathogenesis of this lineage may 
identify susceptible persons, such as younger persons with 
burns and SSTIs, who might benefit from interventions 
such as vaccination with recombinant TSST-1 or S. aureus 
screening and decolonization in the future to prevent the 
occurrence of this life-threatening syndrome.
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